CL2018003270A1 - Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal. - Google Patents
Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal.Info
- Publication number
- CL2018003270A1 CL2018003270A1 CL2018003270A CL2018003270A CL2018003270A1 CL 2018003270 A1 CL2018003270 A1 CL 2018003270A1 CL 2018003270 A CL2018003270 A CL 2018003270A CL 2018003270 A CL2018003270 A CL 2018003270A CL 2018003270 A1 CL2018003270 A1 CL 2018003270A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- carboxylic acid
- pharmaceutically acceptable
- acceptable salt
- same
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 206010028735 Nasal congestion Diseases 0.000 title abstract 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 210000002345 respiratory system Anatomy 0.000 abstract 2
- -1 CARBOXYL Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO COMO INGREDIENTE ACTIVO PARA USAR EN EL TRATAMIENTO Y/O ALIVIO Y/O PREVENCIÓN DE UNA CONGESTIÓN NASAL, UNA ENFERMEDAD INFECCIOSA VIRAL DEL TRACTO RESPIRATORIO O UNA INFLAMACIÓN DE LA GARGANTA. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR Y/O ALIVIAR Y/O PREVENIR CONGESTIÓN NASAL, INFECCIONES VIRALES DEL TRACTO RESPIRATORIO Y/O INFLAMACIÓN DE LA GARGANTA EN UN PACIENTE, QUE COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO O UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO A UN PACIENTE QUE LO NECESITA. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA ALIVIAR LOS SÍNTOMAS ASOCIADOS CON CONGESTIÓN NASAL, INFECCIONES VIRALES DEL TRACTO RESPIRATORIO Y/O INFLAMACIÓN DE LA GARGANTA QUE COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO O UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO A UN PACIENTE QUE LO NECESITA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169882 | 2016-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003270A1 true CL2018003270A1 (es) | 2019-02-22 |
Family
ID=56014856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003270A CL2018003270A1 (es) | 2016-05-17 | 2018-11-16 | Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200000751A1 (es) |
| EP (1) | EP3458043A1 (es) |
| JP (1) | JP6975473B2 (es) |
| KR (1) | KR102430892B1 (es) |
| CN (1) | CN109152754A (es) |
| AU (1) | AU2017266726A1 (es) |
| BR (1) | BR112018072177A2 (es) |
| CA (1) | CA3020485A1 (es) |
| CL (1) | CL2018003270A1 (es) |
| MX (1) | MX2018013475A (es) |
| RU (1) | RU2018143564A (es) |
| SG (2) | SG11201808322PA (es) |
| WO (1) | WO2017198702A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11206245B2 (en) * | 2009-10-14 | 2021-12-21 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| US11948678B2 (en) * | 2009-10-14 | 2024-04-02 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| GB202004690D0 (en) * | 2020-03-31 | 2020-05-13 | Edinburgh Napier Univ | Composition for enhancing immune response of cells |
| US12414928B2 (en) | 2021-05-14 | 2025-09-16 | Rene Dumalaog Javier | Viral inactivation spray and gargling formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063363A (en) * | 1997-05-27 | 2000-05-16 | Goodwin; Gary J | Treatment for upper respiratory tract infections with potassium salts |
| HUP0101369A3 (en) * | 1997-12-23 | 2002-11-28 | Schering Corp | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| JP4847756B2 (ja) * | 2003-09-19 | 2011-12-28 | 大塚製薬株式会社 | ヒトβディフェンシン分泌促進剤 |
| US20070256812A1 (en) * | 2006-04-19 | 2007-11-08 | Wen-Chen Wei | Multidirectional heat dissipating structure |
| US20070286812A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
| CA2886270C (en) * | 2012-10-03 | 2020-04-07 | Proponent Biotech Gmbh | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
-
2017
- 2017-05-17 SG SG11201808322PA patent/SG11201808322PA/en unknown
- 2017-05-17 US US16/097,784 patent/US20200000751A1/en not_active Abandoned
- 2017-05-17 RU RU2018143564A patent/RU2018143564A/ru unknown
- 2017-05-17 AU AU2017266726A patent/AU2017266726A1/en not_active Abandoned
- 2017-05-17 WO PCT/EP2017/061832 patent/WO2017198702A1/en not_active Ceased
- 2017-05-17 SG SG10202006016QA patent/SG10202006016QA/en unknown
- 2017-05-17 CN CN201780029992.2A patent/CN109152754A/zh active Pending
- 2017-05-17 EP EP17723139.6A patent/EP3458043A1/en not_active Withdrawn
- 2017-05-17 MX MX2018013475A patent/MX2018013475A/es unknown
- 2017-05-17 CA CA3020485A patent/CA3020485A1/en not_active Abandoned
- 2017-05-17 KR KR1020187033155A patent/KR102430892B1/ko active Active
- 2017-05-17 JP JP2019513481A patent/JP6975473B2/ja active Active
- 2017-05-17 BR BR112018072177-8A patent/BR112018072177A2/pt not_active IP Right Cessation
-
2018
- 2018-11-16 CL CL2018003270A patent/CL2018003270A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109152754A (zh) | 2019-01-04 |
| SG10202006016QA (en) | 2020-07-29 |
| AU2017266726A1 (en) | 2018-10-11 |
| MX2018013475A (es) | 2019-08-12 |
| JP2019516797A (ja) | 2019-06-20 |
| KR102430892B1 (ko) | 2022-08-09 |
| RU2018143564A3 (es) | 2020-07-23 |
| RU2018143564A (ru) | 2020-06-17 |
| WO2017198702A1 (en) | 2017-11-23 |
| SG11201808322PA (en) | 2018-10-30 |
| EP3458043A1 (en) | 2019-03-27 |
| BR112018072177A2 (pt) | 2019-02-12 |
| JP6975473B2 (ja) | 2021-12-01 |
| CA3020485A1 (en) | 2017-11-23 |
| US20200000751A1 (en) | 2020-01-02 |
| KR20190009294A (ko) | 2019-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CL2018003270A1 (es) | Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal. | |
| MX2018009764A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| MX2010003642A (es) | Nanotecnologia de vacuna. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| MX362804B (es) | Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| MX2020005006A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| AR109012A1 (es) | Sistema de administración transdérmica que contiene galantamina o sales de esta | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| CO2020001887A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático |